The report discusses the reauthorization of Iclusig marketing in the U.S. with a new label and REMS, leading to an upgrade of Ariad shares to Outperform and an increased price target from $3 to $12. The new label indicates Iclusig for specific leukemia patients, and the REMS includes postmarketing requirements. The report highlights the potential for safer administration, new indications, and increased revenue forecasts.
documents/vol00010-efta01465999-pdf.pdf
{"title":"ARIAD Pharmaceuticals, Inc. - Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12","key_people":["Y. Katherine Xu","Filippo Petti"],"document_date":"2013-12-23","document_type":"correspondence","key_locations":["Cambridge, Massachusetts","United States","Europe"],"document_subtype":"Equity Research Report","key_organizations":["ARIAD Pharmaceuticals, Inc.","William Blair & Company, L.L.C.","FDA"]}